Food Safety Modernization Act Third-Party Certification Program User Fee Rate for Fiscal Year 2027
Published Date: 7/30/2026
Notice
Summary
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for recognized accreditation bodies and accredited certification bodies, and the initial and renewal fee rate for accreditation bodies applying to be recognized in the third-party certification program authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). We are also announcing the fee rate for certification bodies applying for direct FDA accreditation.
Analyzed Economic Effects
8 provisions identified: 0 benefits, 8 costs, 0 mixed.
Hourly Work Rates for FY2027 Set
The FDA set the FY2027 fully supported cost per direct work hour at $325 for work that does not require travel and $414 per hour when travel is required. These hourly rates apply from October 1, 2026, through September 30, 2027, and are used to calculate program fees.
Accreditation Body Initial Application Fee
An accreditation body applying for FDA recognition must pay an initial application fee of $56,272. The application fee must be submitted with the application and covers FDA's review and onsite evaluation costs for FY2027 (Oct 1, 2026–Sep 30, 2027).
Annual Fee for Recognized Accreditation Bodies
A recognized accreditation body will be invoiced an annual fee of $2,612 for FY2027 (Oct 1, 2026–Sep 30, 2027). FDA will send annual invoices and payments must be made within 30 days of the invoice date.
Annual Fee for Accredited Certification Bodies
A certification body accredited by a recognized accreditation body must pay an annual fee of $3,266 for FY2027 (Oct 1, 2026–Sep 30, 2027). FDA will send annual invoices and requires payment within 30 days of the invoice date.
Certification Body Direct Accreditation Fee $56,272
A certification body applying for direct FDA accreditation must pay an initial application fee of $56,272 for FY2027. The fee covers FDA review, onsite performance evaluation, and report preparation for the period Oct 1, 2026–Sep 30, 2027.
Accreditation Body Renewal Application Fee
A recognized accreditation body applying for renewal must pay a renewal application fee of $34,311 for FY2027. FDA estimates this covers review, onsite evaluation, and report preparation for renewal applications during Oct 1, 2026–Sep 30, 2027.
Estimated Fees for Directly Accredited Certification Bodies
For certification bodies that would be directly accredited by FDA, FDA estimates a renewal application fee of $34,311 and an annual fee of $26,960 for FY2027. These figures are estimates provided for planning purposes for Oct 1, 2026–Sep 30, 2027.
Payment Rules and Consequences for Nonpayment
Payments must be made within 30 days of the invoice date in U.S. dollars by ACH, credit card (balances under $25,000), or wire transfer. If a recognized accreditation body or accredited certification body fails to pay within 30 days, FDA will suspend recognition or accreditation; failure to pay within 90 days will result in revocation or withdrawal.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15345, Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.
2026-15336, Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).
2026-15346, Biosimilar User Fee Rates for Fiscal Year 2027
Starting October 1, 2026, companies making biosimilar drugs will pay updated fees to the FDA for developing and getting approval for their products. These fees cover new drug development, application reviews, and yearly program costs. This helps the FDA keep biosimilar drug reviews speedy and fair while supporting innovation.
2026-15335, Medical Device User Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA, Agency, or we) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2027, which apply from October 1, 2026, through September 30, 2027, and provides information on how the fees for FY 2027 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.
Previous / Next Documents
Previous: 2026-15336, Food Safety Modernization Act Domestic and Foreign Facility Reinspection, Recall, and Importer Reinspection Fee Rates for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).
Next: 2026-15338, Crow Butte Resources, Inc.; Crow Butte Project and Marsland Expansion Area; Environmental Assessment and Finding of No Significant Impact
The U.S. Nuclear Regulatory Commission (NRC) is considering renewal of Crow Butte Resources, Inc.'s (CBR or the licensee), source and byproduct materials license SUA-1534 for continued in situ recovery (ISR) of uranium at the Crow Butte Project and for construction and operation of a satellite facility and support operations at the Marsland Expansion Area in Crawford, Nebraska, for an additional 20 years. The NRC staff is issuing an environmental assessment (EA) and finding of no significant impact (FONSI).